A delivery system is a technology or method designed to transport an active substance, usually a drug, to the right place in your body at the right time and in the right amount. The simplest example is a pill you swallow, but delivery systems range from skin patches and inhalers to microscopic nanoparticles engineered to seek out cancer cells. The core purpose is always the same: get the therapeutic ingredient where it needs to go while minimizing side effects and waste.
Why Delivery Systems Matter
A drug that works perfectly in a lab dish can fail inside the body for surprisingly basic reasons. It might dissolve poorly in stomach fluid, get broken down by enzymes before it reaches the bloodstream, or spread evenly throughout the body when it only needs to reach one organ. Delivery systems solve these problems by protecting the drug, controlling how fast it’s released, and sometimes directing it to a specific tissue.
The practical impact can be dramatic. In animal studies, shrinking a poorly soluble compound down to nanoparticle size raised its oral bioavailability from 23% to 99%, meaning nearly all of the drug actually reached the bloodstream instead of passing through unused. That kind of improvement can be the difference between a drug that works and one that doesn’t.
Oral Delivery Systems
Swallowing a tablet or capsule is the most common way to take medication, and it’s also the most varied in terms of engineering. A standard immediate-release tablet dissolves quickly and dumps its contents into your digestive tract all at once. Extended-release versions use more sophisticated designs to meter the drug out over hours.
One of the most reliable is the osmotic pump tablet. It has a core containing the drug surrounded by a shell with a tiny laser-drilled hole. When you swallow it, water passes through the shell by osmotic pressure and slowly pushes the drug out through the hole at a steady rate. Because the release is driven by water movement rather than stomach chemistry, it works the same way regardless of whether you’ve eaten, what your stomach pH is, or how quickly food moves through your gut.
Simpler extended-release tablets use matrix systems, where the drug is embedded in a material that erodes or swells gradually. Others use pH-sensitive coatings that stay intact in the acidic stomach but dissolve once they reach the more alkaline environment of the intestines, useful for drugs that would be destroyed by stomach acid or that need to act further down the digestive tract.
Transdermal Patches
Transdermal patches deliver drugs through the skin and directly into the bloodstream, bypassing the digestive system entirely. The first one approved in the United States, in 1979, delivered scopolamine over three days to prevent motion sickness. Nicotine patches followed in 1991, and fentanyl patches for pain management were approved in 1990. Today, roughly 17 drug molecules have FDA-approved transdermal formulations.
Patches work in two broad ways. Passive patches rely on chemical enhancers that loosen the tightly packed outer layer of skin (the stratum corneum) so the drug can diffuse through. These are simple and inexpensive but limited to small, fat-soluble molecules, and there can be a lag time before the drug reaches therapeutic levels. Active patches use external energy to push drugs through the skin. Techniques include iontophoresis (a mild electrical current), microneedles that painlessly puncture the outer skin layer, and ultrasound. These methods can deliver larger molecules and offer more precise control over how quickly the drug enters your system.
Inhalers for Lung Delivery
Inhaled medications take advantage of the lungs’ enormous surface area and rich blood supply to deliver drugs rapidly, either for local effect (as in asthma) or systemic absorption. The two main devices are pressurized metered-dose inhalers (MDIs) and dry powder inhalers (DPIs), and each demands a different breathing technique.
An MDI uses a pressurized canister to spray a pre-measured dose as a fine mist. The challenge is coordination: you need to press the canister and breathe in at exactly the same moment. Mistiming or breathing too shallowly is the most common error, and it significantly reduces how much drug actually reaches the lungs. DPIs eliminate the coordination problem because they’re breath-activated. You inhale sharply, and the force of your breath pulls the powdered drug from the device. The tradeoff is that DPIs require a stronger, more forceful inhalation. People with severe airflow limitation sometimes can’t generate enough force to get a full dose.
Lipid Nanoparticles
Lipid nanoparticles became a household concept during the COVID-19 pandemic, though most people knew them only as the ingredient that made mRNA vaccines possible. Both the Pfizer-BioNTech and Moderna vaccines use lipid nanoparticles to deliver fragile mRNA molecules into your cells.
The problem they solve is straightforward: mRNA is extremely fragile. Enzymes in your blood and tissues would shred it within minutes. Lipid nanoparticles form a tiny fat-based shell around the mRNA, protecting it during transit. Once a nanoparticle is taken up by a cell, it enters a small internal compartment called an endosome. The key trick is escape. The nanoparticle’s lipids are designed to change their electrical charge in the endosome’s acidic environment, which destabilizes the compartment’s membrane and releases the mRNA into the cell’s main interior, where it can be read and translated into protein.
Targeted Nanoparticles for Cancer
Standard chemotherapy drugs circulate through the entire body, killing fast-growing cells wherever they find them. That’s why side effects like hair loss, nausea, and immune suppression are so common. Targeted delivery systems aim to concentrate the drug at the tumor and spare healthy tissue.
The strategy involves attaching molecules called targeting ligands to the surface of a nanoparticle. These ligands recognize and latch onto receptors that are overexpressed on cancer cells but present at low levels on normal cells. Folic acid is one widely studied example: the folate receptor is found at elevated levels on breast, ovarian, lung, colon, and several other cancer types. When a folic acid-coated nanoparticle encounters a cell displaying many folate receptors, it binds and gets pulled inside, delivering its drug payload. Cells with few folate receptors are largely ignored.
Other targeting ligands include antibodies, short protein fragments called peptides, and aptamers (synthetic molecules sometimes called “chemical antibodies” because they match or exceed the binding precision of real antibodies). Each type has tradeoffs in size, stability, and manufacturing cost, but the principle is the same: guide the drug to the right address.
Viral Vectors for Gene Therapy
Gene therapy requires delivering a working copy of a gene into cells that carry a defective one, and the most common courier is a modified virus. Adeno-associated virus (AAV) is the workhorse of the field. It’s a small, naturally occurring virus that has been engineered to carry therapeutic DNA instead of its own genetic material. It can’t cause disease, and different versions (called serotypes) have natural preferences for different tissues, which helps direct the therapy to the right organ.
The list of conditions treated or being treated with AAV-based gene therapy is long and growing. Approved or late-stage examples include therapies for inherited blindness (Leber congenital amaurosis), hemophilia A and B, spinal muscular atrophy, and Duchenne muscular dystrophy. AAV vectors have also entered clinical trials for Alzheimer’s disease, Parkinson’s disease, and several rare metabolic disorders like Sanfilippo syndrome and a condition that causes dangerous ammonia buildup in the blood.
Implantable and Injectable Sustained-Release Systems
For conditions requiring months of continuous medication, implantable and injectable systems remove the burden of daily dosing. One well-studied example is sustained-release naltrexone, used in treating opioid and alcohol addiction. The injectable version is a suspension of naltrexone embedded in a biodegradable polymer that slowly breaks down after being injected into the gluteal muscle. A single shot maintains therapeutic drug levels for about 28 days.
The implantable version takes this further. Small pellets containing naltrexone in a solid biodegradable polymer are surgically placed under the skin using local anesthesia. Depending on the formulation and number of pellets, they can release the drug for two to seven months. For a condition where missing doses can mean relapse, removing the daily decision to take a pill is itself a therapeutic advantage.
Glucose-Responsive “Smart” Systems
The frontier of delivery system design is devices that sense what’s happening in the body and adjust drug release in real time. The most pursued target is a “fully synthetic pancreas” for diabetes: a system that detects rising blood sugar and automatically releases the right dose of insulin, then dials back as glucose levels fall.
The most advanced versions currently in use combine digital insulin pumps with continuous glucose monitors, but these require bulky external hardware. Researchers are working on purely material-based alternatives, including polymer systems and chemically modified insulin molecules that change their activity based on glucose concentration. Modified insulin conjugated with glucose-sensing chemical groups has shown improved blood sugar control in preclinical studies compared to both standard and long-acting insulin. The remaining hurdles are significant: response time needs to be faster, the materials need to be safe for long-term use in the body, and the systems must prove reliable over weeks or months rather than hours.